-+ 0.00%
-+ 0.00%
-+ 0.00%
Earnings Scheduled For March 27, 2026
Share
Listen to the news

Companies Reporting Before The Bell

• Instil Bio (NASDAQ:TIL) is expected to report earnings for its fourth quarter.

• BioXcel Therapeutics (NASDAQ:BTAI) is projected to report quarterly loss at $0.52 per share on revenue of $142 thousand.

• Legence (NASDAQ:LGN) is expected to report quarterly earnings at $0.02 per share on revenue of $618.01 million.

• Werewolf Therapeutics (NASDAQ:HOWL) is likely to report quarterly loss at $0.34 per share on revenue of $600 thousand.

• Humacyte (NASDAQ:HUMA) is estimated to report quarterly loss at $0.13 per share on revenue of $1.44 million.

• Autolus Therapeutics (NASDAQ:AUTL) is projected to report quarterly loss at $0.38 per share on revenue of $23.24 million.

• SBC Medical Group Holding (NASDAQ:SBC) is likely to report quarterly earnings at $0.12 per share on revenue of $46.06 million.

• Yunji (NASDAQ:YJ) is likely to report earnings for its Fiscal Year 2025.

• Huize Holding (NASDAQ:HUIZ) is estimated to report earnings for its Fiscal Year 2025.

• 51 Talk Online Education (AMEX:COE) is likely to report earnings for its fourth quarter.

• Kopin (NASDAQ:KOPN) is projected to report quarterly loss at $0.01 per share on revenue of $11.65 million.

• LM Funding America (NASDAQ:LMFA) is expected to report quarterly loss at $0.45 per share on revenue of $2.80 million.

• TMC The Metals Co (NASDAQ:TMC) is projected to report earnings for its fourth quarter.

• Super League Enterprise (NASDAQ:SLE) is projected to report quarterly loss at $2.98 per share on revenue of $3.58 million.

Companies Reporting After The Bell

• Origin Materials (NASDAQ:ORGN) is likely to report earnings for its fourth quarter.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending